Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Nazy Zomorodian, NP
Advertisement
Articles by Nazy Zomorodian, NP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
2
122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes
3
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
4
121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)
5